The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis

1. WHO coronavirus disease dashboard , https://covid19.who.int/ (accessed 15 September 2020).
Google Scholar2. Mulangu, S, Dodd, LE, Davey, RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293–2303.
Google Scholar | Crossref | Medline3. GS-5734 to assess the antiviral activity, longer-term clearance of Ebola virus, and safety in male Ebola survivors with evidence of Ebola virus persistence in semen , https://clinicaltrials.gov/ct2/show/NCT02818582
Google Scholar4. Sheahan, T, Sims, A, Graham, R, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9: eaal3653.
Google Scholar | Crossref | Medline5. Wang, M, Cao, R, Zhang, L, et al et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269–271.
Google Scholar6. Williamson, BN, Feldmann, F, Schwarz, B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. bioRxiv 2020:2020.04.15.043166.
Google Scholar7. Sheahan, T, Sims, A, Leist, SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon-beta against MERS-CoV. Nat Commun 2020; 11: 222.
Google Scholar | Crossref | Medline8. de Wit, E, Feldmann, F, Cronin, J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA 2020; 117: 6771–6776.
Google Scholar | Crossref | Medline9. Gordon, CJ, Tchesnokov, EP, Feng, JY, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020; 295: 4773–4779.
Google Scholar | Crossref | Medline10. Gordon, CJ, Tchesnokov, EP, Woolner, E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020; 295: 6785–6797.
Google Scholar | Crossref | Medline11. US FDA . Remdesivir letter of EUA, https://www.fda.gov/media/137564/download (accessed 25 July 2020).
Google Scholar12. European Medicines Agency . Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to the member states for remdesivir available for compassionate use, 2020, https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distribution-patients-targeted-conditions-safety-monitoring-adressed_en-2.pdf
Google Scholar13. Summary on compassionate use remdesivir Gilead , https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf (accessed 28 July 2020).
Google Scholar14. Wang, Y, Zhang, D, Du, G, et al. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395: 1569–1578.
Google Scholar | Crossref | Medline15. Goldman, JD, Lye, DCB, Hui, DS, et al. Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med 2020; 383: 1827–1837.
Google Scholar | Crossref | Medline16. Spinner, CD, Gottlieb, RL, Criner, GJ, et al. Effect of remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020; 324: 1048–1057.
Google Scholar | Crossref | Medline17. WHO Solidarity Trial Consortium , Pan, H, Peto, R, et al. Repurposed antiviral drugs for covid-19 – Interim WHO Solidarity Trial results. N Engl J Med 2021; 384: 497–511.
Google Scholar | Crossref | Medline18. Grein, J, Ohmagari, N, Shin, D, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med 2020; 382: 2327–2336.
Google Scholar | Crossref | Medline19. Beigel, JH, Tomashek, KM, Dodd, LE, et al. Remdesivir for the treatment of covid-19 – final report. N Engl J Med 2020; 383: 1813–1826.
Google Scholar | Crossref | Medline20. Antinori, S, Cossu, MV, Ridolfo, AL, et al. Compassionate remdesivir treatment of severe covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in post-treatment hospitalization status. Pharmacol Res 2020; 158: 104899.
Google Scholar | Crossref | Medline21. Dubert, M, Visseaux, B, Isernia, V, et al. Case report study of the first five patients COVID-19 treated with remdesivir in France. Int J Infect Dis 2020; 98: 290–293.
Google Scholar | Crossref | Medline22. Douedi, S, Miskoff, J. Novel coronavirus 2019 (COVID-19): a case report and review of treatments. Medicine 2020; 99: e20207.
Google Scholar | Crossref | Medline23. Burwick, R, Yawetz, S, Stephenson, KE, et al. Compassionate use of remdesivir in pregnant women with severe COVID-19 (Abstract no. 3944 and poster). In: AIDS 2020: COVID-19 conference, https://cattendee.abstractsonline.com/meeting/9307/Presentation/3944
Google Scholar24. Patel, PA, Chandrakasan, S, Mickells, GE, et al. Severe pediatric COVID-19 presenting with respiratory failure and severe thrombocytopenia. Pediatrics 2020; 146: e20201437.
Google Scholar | Crossref | Medline25. Chiotos, K, Tamma, PD, Goldman, DL, et al. Compassionate use of remdesivir in children with severe COVID-19 (Abstract no. 3946 and poster). In: AIDS 2020: COVID-19 conference, https://cattendee.abstractsonline.com/meeting/9307/Presentation/3946
Google Scholar26. Anderson, J, Schauer, J, Bryant, S, et al. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: a case report. Case Rep Womens Health 2020; 27: e00221.
Google Scholar | Medline27. Orf, K, Rogosic, S, Dexter, D, et al. Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection. Br J Haematol 2020; 190: e274–e276.
Google Scholar | Crossref | Medline28. Study to evaluate safety, tolerability, pharmacokinetics and efficacy of remdesivir (GS5734) in participants from birth to <18 years of age with coronavirus disease 2019 (COVID-19) CARAVAN . Clinicaltrials.gov, https://www.clinicaltrials.gov/ct2/show/NCT04431453
Google Scholar29. Fact sheet for health care providers emergency use authorization (EUA) of Veklury® (remdesivir) , https://www.fda.gov/media/137566/download (accessed 29 July 2020).
Google Scholar30. Adamsick, ML, Gandhi, RG, Bidell, MR, et al. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol 2020; 31: 1384–1386.
Google Scholar | Crossref | Medline31. The COVID-19 Investigation Team . First 12 patients with coronavirus disease 2019 (COVID-19) in the United States, 2020, https://www.medrxiv.org/content/10.1101/2020.03.09.20032896v1.full.pdf
Google Scholar32. Lescure, FX, Bouadma, L, Nguyen, D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis 2020; 20: 697–706.
Google Scholar | Crossref | Medline33. Li, J, Fan, JG. Characteristics and mechanism of liver injury in 2019 coronavirus disease. J Clin Transl Hepatol 2020; 8: 13–17.
Google Scholar | Medline34. Zhang, C, Shi, L, Wang, FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020; 5: 428.
Google Scholar | Crossref | Medline35. http://www.aasld.org/ClinicalInsights (accessed 28 July 2020).
Google Scholar36. Remdesivir . https://www.elsevier.com/__data/assets/pdf_file/0008/996767/Remdesivir-Drug-Monograph_28MAY2020.pdf (accessed 30 July 2020).
Google Scholar37. Elsawah, HK, Elsokary, MA, Abdallah, MS, et al. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: systematic review and meta-analysis including network meta-analysis. Rev Med Virol 2020; 31: e2187.
Google Scholar | Medline

留言 (0)

沒有登入
gif